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Direct current therapy (DCT) offers considerable promise as a low-cost, minimally invasive anti-tumour treatment. While the tissue-destructive effects of low, direct electrical currents have been known for many years, development of a clinically acceptable therapy has been slow, hindered, for example, by uncertainties regarding the quantitation of the dose-response relationship. Our previous qualitative study demonstrated that both anodic and cathodic treatments caused prompt and massive tumour necrosis (Dodd et al., 1993) . The present work provides an absolute and relative quantitation of the extent of tumour regression/necrosis with charge and polarity. In common with previous workers, we noted that tumour lysis and volume decrease was extremely rapid after DCT. For other therapies, it has been observed clinically that an undesirable 'tumour lysis syndrome' may result in these circumstances (van der Hoven et al., 1992) . Accordingly, we also examine here the potential systemic consequences of treating tumours by DCT.
Materials and methods
All procedures to be described complied with the Animals (Scientific Procedures) Act 1986 (UK). Male B6DF21 (Paterson) mice, 6-8 weeks old, weight approximately 25 g, were inoculated subcutaneously with a suspension of cells from a low-passage, syngeneic murine mammary carcinoma, T50/80 (Moore, 1988) . Tumours were treated by DCT 6-10 weeks after inoculation when they were approximately spherical and 6-1O mm in diameter. Tumour size was assessed using vernier calipers to measure three orthogonal diameters a, b and c. Tumour volume was calculated using the approximation:
Up to four mice were treated simultaneously while held under general anaesthesia and maintained at a constant temperature of 37°C. Anaesthesia was induced by i.p. injection of ketalar (Park Davis, Pontypool, UK) and maintained using halothane (ICI Pharmaceuticals, Alderley Edge, UK) and oxygen inhalation for the duration of the procedure. Each animal was placed on a copper plate electrode covered in conducting gel (Dracard, Maidstone, UK). The second electrode consisted of a 1 cm length of gold wire, 0.25 mm diameter, spot welded to an 8 cm length of phosphor-bronze wire. This was inserted into the tumour through a 21 G needle which was subsequently removed, and held firmly by a supporting gantry above the mouse with the terminal gold section only in contact with the tumour. A new gold electrode was used after every 2-3 treatments, thus minimising the effects of gradual roughening of the electrode surface due to dissolution of gold when the electrode was made an anode. Before use as anode or cathode, these intratumoral electrodes were sterilised with 70% alcohol. Direct current was passed between the electrodes by means of a computercontrolled, constant-current power supply which continually monitored voltage. The power source used here was designed to maintain a constant current; applied voltage was therefore automatically varied accordingly within the range 1-16 V. For an implanted anode, current and duration of application varied from 1 to 4 mA and 30 to 90 min respectively. For the cathode, values were 1-5 mA and 30-90 min. Different limits of total charge delivered during anodic and cathodic treatments were imposed by mortality of the animals (see below). Animals were randomly allocated to a currenttime-polarity treatment group, with seven test animals and one control animal per group. Controls were exposed to anaesthesia and implantation of the electrode, but no current was passed. After treatment animals were housed in individual cages. Each tumour was measured daily until it had grown to 125% of its pretreatment volume, when the animal was killed using a schedule 1 method.
The initial volume of control tumours varied over the same range as did treated tumours, and this enabled data from controls to be used in a computer program that generated idealised tumour growth curves for any initial tumour volume within that range. Using this program, (i) maximum decrease in tumour volume and (ii) tumour regrowth delay were calculated for each treated tumour, relative to the sizematched control curve. In some cases the decrease in volume was equal to the total initial volume, and in a few cases no regrowth of the tumour was observed, even after several months, i.e. the animals were 'cured' of their tumours. However, in this first series, only those tumours in which partial damage (i.e. less than total volume regression) occurred were used to quantify the effects of treatment. In those tumours in which the relative volume regression was 100%, the absolute volume regression attainable for that dose was unknown.
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Using the same methods as above, further groups of animals were treated with higher charges. Groups were either (i) sacrificed at different times after treatment and their organs subjected to histological examination or (ii) placed under deep terminal anaesthesia, blood taken and biochemical analysis of blood parameters carried out ('Cobras Mira-S' analyser; Roche, Welwyn Garden City, UK).
Statistical methods used were as follows: For calculation of volume regression versus charge and growth delay versus percentage volume regression, a linear-linear regression yielded the best (least-squares) fit to the data. Analysis of biochemical data (treated-untreated) was made by a twosample t-test, significance being taken as P = 95% or greater.
Results
Anodic treatment When volume regression was analysed against various parameters of dose delivered, the best correlation was obtained when plotted against charge, although it did appear that higher currents resulted in greater volume regression for the same charge passed, possibly because of higher rates of production of electrolytic products (see Discussion). Regression analysis of the data showed a linear relationship between the volume of regression induced in the tumour and the charge passed when the electrode in the tumour was an anode (Figure 1 Note that when the gold electrode was made a cathode, the remote copper plate, which then became an anode, showed evidence of dissolution with (non-traumatic) traces of a green cupric chloride deposit visible on the animal's skin by the end of treatment.
Treatment-induced mortality During the course of the experiments described above, the effects of higher dose could not be examined, owing to mortality of the animals. Consequently, experiments were carried out to determine the onset and cause of this mortality which, to our knowledge, has not been previously reported. Tumour-bearing animals were randomly assigned to one of eight groups, each containing six mice. Two groups were used as controls and underwent anaesthesia and implantation of the electrode, but no current was passed. (Figure 1 ).
Discussion
It has been known since the late nineteenth century that low-level direct electrical current can destroy tumour tissue and inhibit tumour growth. Several workers have demonstrated the efficacy of this modality against subcutaneous animal tumour models (Humphrey & Seal, 1959; Schaube et al., 1977; David et al., 1985; Marino et al., 1986) and its potential clinical application (Nordenstrom, 1983) . We have now examined the quantitative relationships between tumour destruction and DCT 'dose'. The results demonstrate a linear relationship between the volume of regression induced and the quantity of charge passed. Moreover, our comparison of the effects of polarity of the electrode implanted in the tumour demonstrates the greater efficacy of the anode over the cathode, the slopes of the lines being 50 ± 2 and 33 ± 2 mm3 coulomb-' respectively. These values can be compared with previously reported values of 21.1 and 22.6 mm3 coulomb-' for anodic treatment of rabbit liver and lung respectively . These authors also reported that cathodic injury was less extensive for any given charge passed. In contrast, cathodic treatment of a fibrosarcoma Sa-1 or melanoma B-16 in mice was reported to be more effective than anodic treatment (Miklavcic et al., 1992) . However, in this case the charges passed were < 1 mA and the tumours were treated at a volume of only about 50mm3. The tumour growth delay resulting from DCT is directly proportional to the volume percentage of the tumour destroyed by that treatment. Again, the slope of the line for anodic treatment is greater than that for cathodic treatment, the difference being statistically significant at the 95% confidence level. This may reflect the different mechanisms of damage occurring at the positive and negative electrodes. When the treatment electrode is an anode, the following reactions take place:
3H2O-2e-*2H30+ + 1/202 2C1 --2e -* C12 In addition to these, there is the anodic dissolution of gold:
Au Previous measurements of the effects of photodynamic therapy (PDT), another modality in which the extent of necrosis predicts growth delay in this tumour model, gave a slope of 0.29 ± 0.03 (Moore et al., 1989) , compared with 0.20 ± 0.01 anode, 0.16 ± 0.01 cathode (this paper). However, this apparently significant difference in the efficacy of PDT compared with DCT may at least in part be -due to the different methods of estimating the proportion of damage. In the case of PDT, volume of tumour necrosis was measured 1 day post treatment by proton magnetic resonance imaging. For DCT, tumour volume was calculated daily from measurement of orthogonal diameters, with minimum volume seen at 3-5 days.
In the present experiments, results were compared irrespective of rate of delivery of the charge, since there was no evidence of any influence of dose rate. If the method is to be used to destroy larger tumour volumes, it may be necessary to use higher currents in order to keep treatment times within acceptable limits. From other work (Samuelsson & J6nsson, 1980) there appears to be no hyperthermic effect for currents below about 80 mA. Thus, it is possible that dose rate effects might become significant on using currents that were an order of magnitude higher.
Determination of the relationships between treatment by direct current and biological response in our experimental model was limited by the mortality of the animals at higher charges. This was found to be a highly reproducible effect, occurring at or above 14.4 C in anode-treated animals and 25.2 C in cathode-treated animals. While no gross changes could be detected in the internal organs of animals subjected to what proved to be a lethal dose, profound changes in blood chemistry were observed (Table I ). As noted, the time interval between treatment and death was the same whether induced by anodic or cathodic treatment, and occurred when destruction of tumour volume exceeded 700 mm3. The experiment was conducted so that treatment resulted in destruction of minimal normal tissue (overlying skin only) and this would therefore contribute little to the observed mortality. All mice used were of approximately the same weight (25 g), and death occurred when destruction of tumour exceeded approximately 0.7 g. The independence of effect from polarity may suggest that the biochemical changes are related more to the mass of tissue undergoing necrosis than to the precise local mechanism inducing that necrosis. As in most murine studies, in these experiments the ratio of tumour mass to body mass is relatively high. Sudden necrosis of a large proportion of that tumour would impose a high metabolic burden on the kidney. Such a picture is seen clinically in the tumour lysis syndrome (usually in treated systemic tumours) and surgical crush syndrome (Better, 1990; van der Hoven et al., 1992) . In both cases, rapid breakdown of tissue leads to release into the blood of intracellular protein, nucleic acid and their breakdown products, many of which are capable of inducing acute renal failure. In addition, intracellular potassium is released in massive quantities and, with renal excretion of that ion greatly reduced, a profound hyperkalaemia results which may be sufficient to induce fatal cardiac arrhythmias. The mortality reported here is indicative of how effective DCT is in destroying tumour tissue and does not reflect a specific adverse effect of the therapy itself. In clinical practice, the tumour load would, in most cases, be insufficient to result in any adverse effects through such a mechanism. Since the DCT treatment is localised rather than systemic, possible adverse effects could be avoided, for example by fractionated treatment, the relative efficacy of which we are currently measuring in the preclinical model.
